NEW YORK – Imagene AI on Tuesday said it closed a $23 million Series B financing round to advance its multi-modal digital pathology foundation models for precision medicine.

纽约——Imagene AI 周二宣布完成了一轮 2300 万美元的 B 轮融资，以推进其用于精准医疗的多模态数字病理基础模型。

Oracle Chairman and CTO Larry Ellison led the round with participation from existing investor Aguras Pathology Investments. The new financing round brings the Miami-based company's total capital raised to $45 million.

甲骨文董事长兼首席技术官拉里·埃里森（Larry Ellison）领投了此轮融资，现有投资者阿古拉斯病理学投资公司（Aguras Pathology Investments）也参与其中。这笔新的融资使这家位于迈阿密的公司的总融资额达到了4500万美元。

'We're developing the core intelligence that allows precision medicine to function as an adaptive, insight-driven system — from real-time trial design to rapid patient identification and more informed clinical decisions,' Imagene AI CEO and Cofounder Dean Bitan said in a statement. 'Our goal is to make every trial more responsive, every insight more actionable, and every patient journey more personalized.'.

“我们正在开发核心智能，使精准医疗能够作为一个自适应、洞察驱动的系统运作——从实时试验设计到快速患者识别以及更明智的临床决策，”Imagene AI首席执行官兼联合创始人迪恩·比坦在一份声明中表示。“我们的目标是让每一次试验更具响应性，每一个洞察更具可操作性，每一位患者的治疗过程更加个性化。”

Imagene AI's foundation model has been trained on over 1.5 million biopsy images. The firm's platform routes histopathology images, molecular profiles, and clinical context through its proprietary foundation models, large language models, and biology-tuned analysis engines. Through a continuously looping process, Imagene AI offers guidance to clinicians and researchers through every stage of a clinical trial.

Imagene AI的基础模型已经过超过150万张活检图像的训练。该公司的平台通过其专有的基础模型、大型语言模型和经过生物学调优的分析引擎，处理组织病理学图像、分子谱和临床背景。通过一个持续循环的过程，Imagene AI在临床试验的每个阶段为临床医生和研究人员提供指导。

.

。

The firm previously raised $21.5 million in a private financing in

该公司此前在私人融资中筹集了 2,150 万美元

May 2022

2022年5月

, which included $3 million from a seed financing round led by Blumberg Capital and $18.5 million from a Series A round led by Ellison and individual investors David Agus and Eyal Gura.

，其中包含由Blumberg Capital领投的300万美元种子轮融资，以及由Ellison和个体投资者David Agus和Eyal Gura领投的1850万美元A轮融资。

“Imagene AI’s ability to unite imaging, omics, and clinical data in a single foundation model is exactly the kind of breakthrough we believe will drive the next generation of drugs and diagnostics,” said Ellison. “Their approach opens the door to a more adaptive, biologically fluent era of precision medicine.”.

“Imagene AI能够将影像、组学和临床数据整合到一个基础模型中，这正是我们认为将推动下一代药物和诊断发展的突破，”埃里森表示。“他们的方法为更灵活、更生物通晓的精准医学时代打开了大门。”

Imagene inked a collaboration with Tempus AI

Imagene与Tempus AI达成了合作。

in February

二月

to launch an artificial intelligence-based biomarker prediction panel for non-small cell lung cancer. The company also signed a partnership agreement centered on AI-based molecular profiling with the Hoag health system in southern California in August 2023 and a deal in September 2024 with Oracle to launch its pan-cancer foundation model on the Oracle Cloud Infrastructure.

推出基于人工智能的非小细胞肺癌生物标志物预测平台。该公司还于2023年8月与南加州的Hoag卫生系统签署了一项以人工智能为基础的分子分析为中心的合作协议，并于2024年9月与甲骨文达成协议，将其泛癌基础模型部署在甲骨文云基础设施上。

.

。

The company said it is now expanding its strategic collaborations, including its partnership with Tempus, to deliver rapid predictive assays to more clinicians and patients.

该公司表示，现在正在扩大其战略合作伙伴关系，包括与Tempus的合作，以为更多临床医生和患者提供快速的预测分析。